Agriculture Reference
In-Depth Information
Table 13.2
The residue or substance group measured for each commodity type
Group
Compound type
Bovine, ovine, porcine,
caprine, equine
Poultry
Aquaculture
and finfish
Milk
Eggs
Rabbit, wild/
farmed game
a
Honey
A1
Stilbenes, salts and esters
X
X
X
X
A2
Antithyroid drugs
X
X
X
A3
Steroids
X
X
X
X
A4
RALs and zeranol
X
X
X
A5
ß-Agonists
X
X
X
A6
Annex IV compounds
X
X
X
X
X
X
X
B1
Antibacterials
X
X
X
X
X
X
X
B2a
Anthelmintics
X
X
X
X
X
B2b
Anticoccidials
X
X
X
X
B2c
Carbamates and
pyrethroids
X
X
X
X
B2d
Sedatives
X
B2e
NSAIDs
X
X
X
X
B2f
Others
B3a
OCs and PCBs
X
X
X
X
X
X
X
B3b
OPs
X
X
X
B3c
Elements
X
X
X
X
X
X
B3d
Mycotoxins
X
X
X
X
B3e
Dyes
X
X
B3f
Others
a
Elements only for wild game.
plan setting out the guarantees and residue testing
programme which it offers concerning the monitoring
of food of animal origin destined for the European
market for the groups of residues and substances set
out in Annex I of that Directive. The plans submitted
by third countries must offer a level of protection to
the consumer that is at least equivalent to that offered
by member state's monitoring plans. Third countries
must establish a central competent authority that is
responsible for:
•
Drawing up a residue monitoring plan
•
Co-ordinating the activities of the central and regional
departments
•
Residue monitoring and co-ordinating the prevention
of the fraudulent use of substances and products on
farms
•
Collecting the results and sending them to the
Commission, by not later than 31 March of each
year
Testing procedures and performance
characteristics
Testing procedures
Within the EU, there are no official, prescribed methods
of analysis for residues of veterinary medicinal products
in food of animal origin. All member states are free to
implement whatever strategies they wish to meet the
EU's legislative requirements. However, all methods
employed by the member states must meet the perfor-
mance criteria laid down in Commission Decision
2002/657/EC (2002). The key criteria set out in this doc-
ument will be described later in this chapter in section
'Analytical methods: Technical aspects. Most EU member
states operate a two-tier testing system to minimise the
cost and maximise the efficiency and coverage of their
testing programmes. Traditionally, broad-spectrum,
high-throughput, low-cost screening tests have been
used to sift samples into those which are 'negative' and
those which are 'potentially positive. Such tests now span
the entire analytical spectrum from microbiological
growth inhibition tests, commercial ELISA test kits,
high-performance liquid chromatography (HPLC), to
mass spectrometry (MS) (MS, single quadrupole, or
MS
n
, triple quadrupole, ion trap, etc.). All 'potentially
positive' samples must then be confirmed using a second
Monitoring of compliance with this Directive is
accomplished by regular audits of legislation, controls
and laboratory monitoring by officials of the European
Commission's FVO, who may be accompanied by
national technical experts to assist in the evaluation
process.
